Actively Recruiting
A Study of AMDX-2011P in Participants With Alzheimer's Disease
Led by Amydis Inc. · Updated on 2026-02-13
25
Participants Needed
1
Research Sites
81 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
CONDITIONS
Official Title
A Study of AMDX-2011P in Participants With Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of Alzheimer's Disease with positive amyloid beta signal via PET brain scan
- Willingness to consent to apolipoprotein E (APOE) genotyping
- Ability to fixate and undergo retinal imaging of both eyes
You will not qualify if you...
- Any physical or psychological condition that may prevent completion of the study per protocol
- Diagnosis or suspicion of glaucoma in either eye as determined by an ophthalmologist
- Diagnosis of intermediate dry, wet/neovascular, or geographic atrophy forms of age-related macular degeneration in either eye
- Clinically significant laboratory abnormalities as assessed by the investigator
- Prolonged QTcF (>450 ms for males, >470 ms for females), cardiac arrhythmia, or significant resting ECG abnormalities as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Associated Retina Consultants
Phoenix, Arizona, United States, 85020
Actively Recruiting
Research Team
M
Matthew Lehman
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here